Advertisement
Advertisement
Money /
Money News
Related Topics:
Banking & finance
China’s private sector
China’s drug makers are speeding up – will AI be their secret weapon?
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
18 Apr 2026 - 11:05AM
Banking & finance
Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios
15 Apr 2026 - 8:13PM
Banking & finance
China healthcare stocks shine in Hong Kong amid Middle East turmoil
10 Apr 2026 - 4:25PM
Banking & finance
OKX Ventures, HashKey Capital back Vietnam crypto platform’s pilot scheme bid
Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.
10 Apr 2026 - 11:04AM
This photo taken on February 12, 2026 shows a Vietnamese cryptocurrency investor looking at the latest bitcoin values on a smartphone in Hanoi. Photo: AFP
Banking & finance
Mainland China and Hong Kong IPOs drive Citic to the top of banking fee rankings
Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.
9 Apr 2026 - 5:02PM
Banking & finance
Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates
Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.
8 Apr 2026 - 10:53AM
Advertisement
Advertisement
Advertisement
China’s private sector
Rights to antibody drug from China’s Keymed change hands in US acquisition
Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.
24 Mar 2026 - 4:21PM
Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Banking & finance
Iran conflict drives fund managers to slash risk and hoard cash: BofA survey
Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.
18 Mar 2026 - 4:40PM
Banking & finance
Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says
Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.
18 Mar 2026 - 9:31AM
China’s private sector
US reshoring drive casts shadow over China’s contract drug makers, analyst says
Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.
18 Mar 2026 - 10:10AM
Banking & finance
Hong Kong attracts wave of biotech IPO filings amid AI drug research boom
More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.
16 Mar 2026 - 2:38PM
The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
Biomedicine: Companies
In a first for China, Neuracle’s brain-computer interface wins approval
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.
14 Mar 2026 - 12:54AM
Banking & finance
Hong Kong family offices take long view despite Iran war, HKMA affiliate says
Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.
10 Mar 2026 - 7:45PM
Banking & finance
China investors energise Hong Kong biotech stocks. Is foreign money missing out?
Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.
10 Mar 2026 - 5:26PM
Made in China 2025
China biotech outlicensing tops US$52 billion in first 2 months
The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.
5 Mar 2026 - 11:01AM
The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
Two Sessions 2026
Healthcare investors looking to ‘two sessions’ for clarity on drug pricing
Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.
4 Mar 2026 - 9:05AM
Made in China 2025
Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals
Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.
1 Mar 2026 - 12:00PM
Advertisement
Advertisement
Advertisement
Hong Kong stock market
The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?
After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.
28 Feb 2026 - 1:44PM
Illustration: Lau Ka-kuen
Made in China 2025
After boost from viral dance challenge, Chinese medicine firm’s shares languish
Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.
22 Feb 2026 - 2:00PM
IPO
Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong
The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.
12 Feb 2026 - 8:00AM
Made in China 2025
Capital injection: China backs AI drug makers in self-reliance drive
A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.
11 Feb 2026 - 5:14PM
Made in China 2025
Chinese healthcare firms expand overseas to support growing expat community
Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.
11 Feb 2026 - 5:08PM
Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance
Mainland China’s investors pour into Hong Kong-listed drug stocks
An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.
10 Feb 2026 - 4:31PM
Banking & finance
China slashes wait times for loss-making tech firms seeking refinancing, fundraising
Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.
10 Feb 2026 - 11:26AM
videocam
Made in China 2025
Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.
6 Feb 2026 - 5:00PM
Help preserve 120 years of quality journalism.
SUPPORT NOW
